BiotechTube
Home/MabTics/Nam‑Kyung Lee, Ph.D.
NL

Nam‑Kyung Lee, Ph.D.

CEO

MabTics

Therapeutic Areas

OncologyVascular DiseaseOphthalmologyImmunology

MabTics Pipeline

DrugIndicationPhase
MT-101Therapeutic angiogenesis, tumor vessel normalization, diabetic retinopathy, AMD, sepsisPreclinical
MT-103Wet age‑related macular degenerationPreclinical
MT-201Anti‑thromboinflammatory indication for vascular inflammation and thrombosisPreclinical
MT-40xTumor‑targeting antibodies for solid tumorsPreclinical

Leadership Team at MabTics

JM
Jeong‑Ki Min, Ph.D.
CTO / Chairman
JS
Jinhoi Song, Ph.D.
Senior Scientist, R&D
JL
Jaemin Lee, Ph.D.
Senior Scientist, New Drug Research
MK
Min‑Gi Kwon, Ph.D.
Research Scientist, New Drug Research
View full MabTics profile